| human | Q5 |
| P691 | NL CR AUT ID | xx0308513 |
| P856 | official website | https://portal.findresearcher.sdu.dk/en/persons/b95f09d8-f647-43e3-b6dd-f6919b2ab0cc |
| P496 | ORCID iD | 0000-0002-3059-2356 |
| P1153 | Scopus author ID | 7102111742 |
| P27 | country of citizenship | Denmark | Q35 |
| P69 | educated at | Aarhus University | Q924265 |
| Esbjerg Statsskole | Q12310593 | ||
| P108 | employer | University of Southern Denmark | Q2166335 |
| Odense University | Q3436286 | ||
| P101 | field of work | chemistry | Q2329 |
| biochemistry | Q7094 | ||
| thrombosis | Q261327 | ||
| cardiovascular disease | Q389735 | ||
| clinical biochemistry | Q10904290 | ||
| P735 | given name | Jørgen | Q13409273 |
| Jørgen | Q13409273 | ||
| P1412 | languages spoken, written or signed | English | Q1860 |
| Danish | Q9035 | ||
| P1559 | name in native language | Jørgen Jespersen | |
| P106 | occupation | researcher | Q1650915 |
| P21 | sex or gender | male | Q6581097 |
| Q42662488 | A 1-year study to compare the hemostatic effects of oral contraceptive containing 20 microg of ethinylestradiol and 100 microg of levonorgestrel with 30 microg of ethinylestradiol and 100 microg of levonorgestrel. |
| Q70669688 | A comparison of the effects of cimetidine and epsilon-aminocaproic acid on fibrinolysis induced by activators of plasminogen and on fibrin formation |
| Q51549706 | A high-fat meal does not activate blood coagulation factor VII in minipigs. |
| Q41013958 | A new automated method for continuous registration of factor VII activation in vitro. Activation is accelerated by the concentration of factor VII and the activity state of the protein. |
| Q71587451 | A study of the conditions and accuracy of the thrombin time assay of plasma fibrinogen |
| Q74503136 | Absence of prothrombin mutation in Inuit (Greenland Eskimos) |
| Q45878722 | Activity of recombinant factor VIIa under different conditions in vitro: effect of temperature, pH, and haemodilution. |
| Q70960010 | Acute pancreatitis with disseminated intravascular coagulation treated with heparin and plasma |
| Q36787643 | Anticoagulants in heart disease: current status and perspectives |
| Q70884528 | Antithrombin-III and Platelets in Haemodialysis Patients |
| Q51559625 | Are olive oil diets antithrombotic? Diets enriched with olive, rapeseed, or sunflower oil affect postprandial factor VII differently. |
| Q72825955 | Assessment of endothelial function during oral contraception in women with insulin-dependent diabetes mellitus |
| Q51567999 | Association of factor VII protein concentration with lifestyle factors. |
| Q79969822 | Comparison of local International Sensitivity Index calibration and 'Direct INR' methods in correction of locally reported International Normalized Ratios: an international study |
| Q77425053 | DNA-polymorphisms and plasma levels of vascular disease risk factors in Greenland Inuit--is there a relation with the low risk of cardiovascular disease in the Inuit? |
| Q72783558 | Deep venous thrombosis in patients with acute myocardial infarction diagnosed by the 99mTc-plasmin test |
| Q41722179 | Diet and blood coagulation factor VII--a key protein in arterial thrombosis. |
| Q51572143 | Dietary fish oil (4 g daily) and cardiovascular risk markers in healthy men. |
| Q87286315 | Difference in fibrinolytic capacity in young patients with venous thrombosis or ischaemic stroke |
| Q72065556 | Differences between functional and immunologic determinations of plasma antithrombin during the treatment of disseminated intravascular coagulation by infusion of antithrombin III concentrate |
| Q72379489 | Disseminated intravascular coagulation and the balance between blood coagulation and fibrinolysis |
| Q70030354 | Distinction by radioisotope technique of a subgroup with increased thrombophilic potential among patients submitted to major abdominal surgery |
| Q70960458 | Does low protein concentration of tissue-type plasminogen activator predict a low risk of spontaneous deep vein thrombosis? |
| Q59057086 | Effect of long-term hormone replacement therapy on tissue factor pathway inhibitor and thrombin activatable fibrinolysis inhibitor in healthy postmenopausal women: a randomized controlled study |
| Q88545062 | Effectiveness and safety of vitamin K-antagonists in an anticoagulant clinic |
| Q72127817 | Effects of contraceptive steroids on cardiovascular risk factors in women with insulin-dependent diabetes mellitus |
| Q44232645 | Effects of different progestin regimens in hormone replacement therapy on blood coagulation factor VII and tissue factor pathway inhibitor. |
| Q70529847 | Effects of monophasic low-dose oral contraceptives on fibrin formation and resolution in young women |
| Q51379285 | Effects on markers of inflammation and endothelial cell function of three ad libitum diets differing in type and amount of fat and carbohydrate: a 6-month randomised study in obese individuals. |
| Q43649477 | Evidence for a role of factor XII-dependent fibrinolysis in cardiovascular diseases |
| Q53177505 | External quality assessment (EQA) for CoaguChek monitors. |
| Q46659852 | Factor VII-activating protease in patients with acute deep venous thrombosis. |
| Q41113389 | Fasting blood coagulation and fibrinolysis of young adults unchanged by reduction in dietary fat content |
| Q50556453 | Fasting serum insulin levels and coronary heart disease in a Danish cohort: 17-year follow-up |
| Q35672001 | Fat consumption and factor VII coagulant activity |
| Q52733637 | Fibrin clot structure - pro-fibrinolytic effect of oral contraceptives in apparently healthy women. |
| Q50964356 | Gender Differences in Fibrin Polymerization and Lysability of Fibrin in Patients with Atrial Fibrillation. |
| Q53118400 | General mechanisms of coagulation and targets of anticoagulants (Section I). Position Paper of the ESC Working Group on Thrombosis--Task Force on Anticoagulants in Heart Disease. |
| Q58301528 | Genetic Influence on Inflammation Variables in the Elderly |
| Q58301440 | Genetic variation in estrogen receptor, C-reactive protein and fibrinogen does not predict the plasma levels of inflammation markers after longterm hormone replacement therapy |
| Q83941709 | INR derivation with the PT/INR Line simplified using a spreadsheet from the world wide web |
| Q87901869 | Impact of point-of-care international normalized ratio monitoring on quality of treatment with vitamin K antagonists in non-self-monitoring patients: a cohort study: comment |
| Q73333607 | In vitro effects of heparin and tissue factor pathway inhibitor on factor VII assays. possible implications for measurements in vivo after heparin therapy |
| Q36058875 | Increased fibrinolytic potential induced by gliclazide in type I and type II diabetic patients |
| Q72716242 | Individual levels of plasma alpha 2-antiplasmin and alpha 2-macroglobulin during the normal menstrual cycle and in women on oral contraceptives low in oestrogen |
| Q37012342 | Induction and Possible Role of Fibrinolysis in Diabetes Mellitus |
| Q44518799 | Inflammation, thrombosis and atherosclerosis: results of the Glostrup study. |
| Q70924512 | Influence of plasma platelets on activated protein C resistance assay |
| Q50233503 | Internal quality control of PCR-based genotyping methods in research studies and patient diagnostics. |
| Q73078670 | Internal quality control of PCR-based genotyping methods: practical experiences |
| Q45873540 | International collaborative study for the calibration of proposed International Standards for thromboplastin, rabbit, plain, and for thromboplastin, recombinant, human, plain |
| Q67678146 | Interrelationship between coagulant activity and tissue-type plasminogen activator (t-PA) system in acute ischaemic heart disease. Possible role of the endothelium |
| Q74605009 | Is factor VII protein concentration (FVII:Ag) a thrombotic risk indicator? |
| Q60233037 | Lipoprotein profile of a Greenland Inuit population. Influence of anthropometric variables, Apo E and A4 polymorphism, and lifestyle |
| Q51394056 | Long-term effects on haemostatic variables of three ad libitum diets differing in type and amount of fat and carbohydrate: a 6-month randomised study in obese individuals. |
| Q73013551 | Longevity is independent of common variations in genes associated with cardiovascular risk |
| Q53741600 | Lowering of the dosage of intravenous heparin hemodialysis by priming with subcutaneous heparin |
| Q80206526 | Lupus anticoagulant is significantly associated with inflammatory reactions in patients with suspected deep vein thrombosis |
| Q87416787 | Lysability of fibrin clots is a potential new determinant of stroke risk in atrial fibrillation |
| Q43816508 | Mean transit times and the sites of synthesis and catabolism of tissue plasminogen activator and plasminogen activator inhibitor type 1 in young subjects. |
| Q51557700 | Metabolic and fibrinolytic response to changed insulin sensitivity in users of oral contraceptives. |
| Q71409335 | Modification of the immediate plasmin inhibition assay to secure linearity of the reference curve with the chromogenic substrate S-2251 |
| Q53387578 | Multicentre evaluation of commercial kit methods: plasminogen activator inhibitor activity. |
| Q34267825 | New oral anticoagulants in atrial fibrillation and acute coronary syndromes: ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease position paper |
| Q51595192 | Non-fasting factor VII coagulant activity (FVII:C) increased by high-fat diet. |
| Q61668950 | Non-vitamin K antagonist oral anticoagulants (NOACs): No longer new or novel |
| Q72814965 | On the diagnosis of deep venous thrombosis in patients at risk |
| Q50999710 | Oral anticoagulants in coronary heart disease (Section IV). Position paper of the ESC Working Group on Thrombosis - Task Force on Anticoagulants in Heart Disease. |
| Q86701182 | Parenteral anticoagulants in heart disease: current status and perspectives (Section II). Position paper of the ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease |
| Q44773326 | Phase III studies on novel oral anticoagulants for stroke prevention in atrial fibrillation: a look beyond the excellent results: a rebuttal. |
| Q93895694 | PlA1/A2 polymorphism of platelet glycoprotein IIIa and risk of cardiovascular disease |
| Q73966805 | Plasma concentrations of blood coagulation factor VII measured by immunochemical and amidolytic methods |
| Q84518293 | Plasma factor VII-activating protease is increased by oral contraceptives and induces factor VII activation in-vivo |
| Q71699767 | Plasminogen activator activity and plasma-coagulum lysis measured by use of optimized fibrin gel structure preformed in microtiter plates |
| Q67883906 | Possible role of vascular intima for generation of coagulant activity in patients undergoing coronary thrombolysis with recombinant tissue-type plasminogen activator. A randomized, placebo-controlled study |
| Q47192690 | Postprandial coagulation activation in overweight individuals after weight loss: acute and long-term effects of a high-monounsaturated fat diet and a low-fat diet. |
| Q46290245 | Randomized controlled trial of cholecalciferol supplementation in chronic kidney disease patients with hypovitaminosis D. |
| Q40873749 | Salicylate hepatitis in rheumatic fever |
| Q70872271 | Termination of Pregnancy in a Woman with Hereditary Antithrombin Deficiency under Antithrombotic Protection with Subcutaneous Heparin and Infusion of Plasma |
| Q31129827 | The Emerging Risk Factors Collaboration: analysis of individual data on lipid, inflammatory and other markers in over 1.1 million participants in 104 prospective studies of cardiovascular diseases |
| Q70328958 | The assay of factor Xa on a centrifugal analyzer |
| Q46621922 | The clinical evaluation of International Normalized Ratio variability and control in conventional oral anticoagulant administration by use of the variance growth rate. |
| Q73425532 | The effect of chemical anti-inhibitors on fibrinolytic enzymes and inhibitors |
| Q74231173 | The effect of low-dose acetylsalicylic acid on bleeding after transurethral prostatectomy--a prospective, randomized, double-blind, placebo-controlled study |
| Q42714228 | The influence of VKORC1 and CYP2C9 gene sequence variants on the stability of maintenance phase warfarin treatment. |
| Q53075187 | The prothrombin time/international normalized ratio (PT/INR) Line: derivation of local INR with commercial thromboplastins and coagulometers – two independent studies |
| Q70987669 | The transient transfer of plasma antithrombin-III to an extraplasmatic body compartment during haemodialysis |
| Q70299139 | The use of evacuated glass tubes for collection of blood samples for fibrinolytic assays |
| Q67967472 | The variability of and associations between measures of blood coagulation, fibrinolysis and blood lipids |
| Q81577518 | Tissue factor pathway inhibitor relates to fibrin degradation in patients with acute deep venous thrombosis |
| Q50543668 | Venous thrombosis is not increased in younger women on genuine oestrogen postmenopausal hormonal replacement therapy: results from the Danish Osteoporosis Prevention Study (DOPS). |
| Q86719687 | Vitamin K antagonists in heart disease: current status and perspectives (Section III). Position paper of the ESC Working Group on Thrombosis--Task Force on Anticoagulants in Heart Disease |
| Q53090842 | Warfarin or dabigatran for treatment of atrial fibrillation. |
| Q72745877 | [Hemostatic balance during treatment with the newest contraceptives] |
| Jørgen Jespersen (professor) | wikipedia |
Search more.